Clessbio employs a "dual-driver model" combining in-house R&D and strategic partnerships to build an innovative pipeline. The company currently has an super long-acting growth hormone program advancing to the preclinical candidate stage, with additional programs in endocrinology, metabolism, and autoimmune diseases undergoing laboratory-stage research.
JY007 is a super long-acting growth hormone that has demonstrated favorable activity and safety profiles in both in vitro and in vivo studies. PK and PD data from mice and NHPs demonstrate that JY007 has the potential to achieve a dosing interval of every 3-4 weeks. In contrast, currently marketed and clinical-stage long-acting growth hormone products necessitate weekly injections, positioning JY007 as a potential best-in-class long-acting growth hormone therapy.
